Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study
| Autor: | Hisao, Mori, Hareaki, Yamamoto, Hiroshi, Ukai, Shouhei, Yuasa, Kazumi, Nakajima, Takehiko, Mikawa, Masamichi, Niizuma, Kouichi, Hirao, Satoshi, Umemura |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty Angiotensin receptor Evening Physiology Diastole Tetrazoles Blood Pressure Drug Administration Schedule law.invention Angiotensin Receptor Antagonists Randomized controlled trial law Internal medicine Internal Medicine medicine Albuminuria Humans Antihypertensive Agents Morning Aged Cardio-Renal Syndrome Dose-Response Relationship Drug business.industry Imidazoles Blood Pressure Monitoring Ambulatory Middle Aged Circadian Rhythm Blood pressure Treatment Outcome Anesthesia Creatinine Ambulatory Hypertension Cardiology Female Cardiology and Cardiovascular Medicine Olmesartan business medicine.drug |
| Zdroj: | Hypertension research : official journal of the Japanese Society of Hypertension. 36(3) |
| ISSN: | 1348-4214 |
| Popis: | Whether the time of administering the angiotensin receptor antagonist olmesartan influences antihypertensive and renoprotective effectiveness remains unclear. This study compared the effects of olmesartan on morning home blood pressure (MHBP), office BP (OBP) and renoprotective parameters between morning and evening administration. A total of 218 patients with primary hypertension were randomly assigned to receive olmesartan once daily in the morning (morning-dose group) or evening (evening-dose group), and 188 completed the study protocol (morning-dose group, n=95; evening-dose group, n=93). In both groups, morning home systolic BP, morning home diastolic BP, office systolic BP and office diastolic BP decreased significantly. There was no significant difference between the groups in MHBP or OBP after 6 months of treatment. The urinary albumin-to-creatinine ratio (UACR) decreased from 13.9 to 6.9 mg g−1 (geometric means, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|